The effect of combined low-frequency repetitive transcranial magnetic stimulation（LF r TMS） and virtual reality（VR） training in patients after stroke was assessed. In a double-blind randomized controlled trial, 11...The effect of combined low-frequency repetitive transcranial magnetic stimulation（LF r TMS） and virtual reality（VR） training in patients after stroke was assessed. In a double-blind randomized controlled trial, 112 patients with hemiplegia after stroke were randomly divided into two groups： experimental and control. In experimental group, the patients received LF r TMS and VR training treatment, and those in control group received sham r TMS and VR training treatment. Participants in both groups received therapy of 6 days per week for 4 weeks. The primary endpoint including the upper limb motor function test of Fugl-meyer assessment（U-FMA） and wolf motor function test（WMFT）, and the secondary endpoint including modified Barthel index（MBI） and 36-item Short Form Health Survey Questionnaire（SF-36） were assessed before and 4 weeks after treatment. Totally, 108 subjects completed the study（55 in experimental group and 53 in control group respectively）. After 4-week treatment, the U-FMA scores [mean difference of 13.2, 95% confidence interval（CI） 3.6 to 22.7, P〈0.01], WMFT scores（mean difference of 2.9, 95% CI 2.7 to 12.3, P〈0.01）, and MBI scores（mean difference 16.1, 95% CI 3.8 to 9.4, P〈0.05） were significantly increased in the experimental group as compared with the control group. The results suggested the combined use of LF r TMS with VR training could effectively improve the upper limb function, the living activity, and the quality of life in patients with hemiplegia following subacute stroke, which may provide a better rehabilitation treatment for subacute stroke.展开更多
The aim of this study was to summarize the efficacy and tolerability of rotigotine in the treatment of primary restless legs syndrome（RLS）. Pub Med, EMBASE, and Cochrane Central Register of Controlled Trials（CENTRA...The aim of this study was to summarize the efficacy and tolerability of rotigotine in the treatment of primary restless legs syndrome（RLS）. Pub Med, EMBASE, and Cochrane Central Register of Controlled Trials（CENTRAL） were searched for English-language randomized controlled trials（RCTs） that assessed the effectiveness of rotigotine for RLS. The pooled mean change from baseline in International RLS（IRLS） Study Group Rating Scalescore and relative risk（RR） of response based on the Clinical Global Impression-Improvement（CGI-I） scale score were applied to evaluate the outcomes. The pooled proportions of adverse events（AEs） were also estimated. Six RCTs were included. The meta-analysis showed a favorable effectiveness of rotigotine versus placebo on RLS [mean change on IRLS score： mean difference（MD）=–4.80; 95% confidence interval（CI）： –5.90 to –3.70; P〈0.00001 and RR of response on CGI-I was 2.19; 95% CI： 1.86 to 2.58, P〈0.00001]. The most common AEs were application site reactions, nausea, headache and fatigue. In general, rotigotine was well-tolerated in patients with primary RLS. Based on the findings from the meta-analysis, rotigotine was more significantly efficacious in the treatment of RLS than placebo. Nevertheless, long-term studies and more evidence of comparisons of rotigotine with other dopamine agonists are needed.展开更多
文摘The effect of combined low-frequency repetitive transcranial magnetic stimulation（LF r TMS） and virtual reality（VR） training in patients after stroke was assessed. In a double-blind randomized controlled trial, 112 patients with hemiplegia after stroke were randomly divided into two groups： experimental and control. In experimental group, the patients received LF r TMS and VR training treatment, and those in control group received sham r TMS and VR training treatment. Participants in both groups received therapy of 6 days per week for 4 weeks. The primary endpoint including the upper limb motor function test of Fugl-meyer assessment（U-FMA） and wolf motor function test（WMFT）, and the secondary endpoint including modified Barthel index（MBI） and 36-item Short Form Health Survey Questionnaire（SF-36） were assessed before and 4 weeks after treatment. Totally, 108 subjects completed the study（55 in experimental group and 53 in control group respectively）. After 4-week treatment, the U-FMA scores [mean difference of 13.2, 95% confidence interval（CI） 3.6 to 22.7, P〈0.01], WMFT scores（mean difference of 2.9, 95% CI 2.7 to 12.3, P〈0.01）, and MBI scores（mean difference 16.1, 95% CI 3.8 to 9.4, P〈0.05） were significantly increased in the experimental group as compared with the control group. The results suggested the combined use of LF r TMS with VR training could effectively improve the upper limb function, the living activity, and the quality of life in patients with hemiplegia following subacute stroke, which may provide a better rehabilitation treatment for subacute stroke.
文摘The aim of this study was to summarize the efficacy and tolerability of rotigotine in the treatment of primary restless legs syndrome（RLS）. Pub Med, EMBASE, and Cochrane Central Register of Controlled Trials（CENTRAL） were searched for English-language randomized controlled trials（RCTs） that assessed the effectiveness of rotigotine for RLS. The pooled mean change from baseline in International RLS（IRLS） Study Group Rating Scalescore and relative risk（RR） of response based on the Clinical Global Impression-Improvement（CGI-I） scale score were applied to evaluate the outcomes. The pooled proportions of adverse events（AEs） were also estimated. Six RCTs were included. The meta-analysis showed a favorable effectiveness of rotigotine versus placebo on RLS [mean change on IRLS score： mean difference（MD）=–4.80; 95% confidence interval（CI）： –5.90 to –3.70; P〈0.00001 and RR of response on CGI-I was 2.19; 95% CI： 1.86 to 2.58, P〈0.00001]. The most common AEs were application site reactions, nausea, headache and fatigue. In general, rotigotine was well-tolerated in patients with primary RLS. Based on the findings from the meta-analysis, rotigotine was more significantly efficacious in the treatment of RLS than placebo. Nevertheless, long-term studies and more evidence of comparisons of rotigotine with other dopamine agonists are needed.
